Literature DB >> 29465709

An Illustration of the Potential Health and Economic Benefits of Combating Antibiotic-Resistant Gonorrhea.

Harrell W Chesson1, Robert D Kirkcaldy, Thomas L Gift, Kwame Owusu-Edusei, Hillard S Weinstock.   

Abstract

Preventing the emergence of ceftriaxone-resistant Neisseria gonorrhoeae can potentially avert hundreds of millions of dollars in direct medical costs of gonorrhea and gonorrhea-attributable HIV infections. In the illustrative scenario we examined, emerging ceftriaxone resistance could lead to 1.2 million additional N. gonorrhoeae infections within 10 years, costing $378.2 million.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29465709      PMCID： PMC6724164          DOI： 10.1097/OLQ.0000000000000725

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN： 0148-5717            Impact factor:   2.830


  9 in total

1.  Ciprofloxacin May be Efficacious in Treating Wild-Type Gyrase A Genotype Neisseria gonorrhoeae Infections.

Authors:  Lao-Tzu Allan-Blitz; Peera Hemarajata; Romney M Humphries; Mabel Kimble; Sam Elias; Jeffrey D Klausner
Journal:  Sex Transm Dis       Date:  2018-04       Impact factor: 2.830

2.  Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.

Authors:  Sami L Gottlieb; Francis Ndowa; Edward W Hook; Carolyn Deal; Laura Bachmann; Laith Abu-Raddad; Xiang-Sheng Chen; Ann Jerse; Nicola Low; Calman A MacLennan; Helen Petousis-Harris; Kate L Seib; Magnus Unemo; Leah Vincent; Birgitte K Giersing
Journal:  Vaccine       Date:  2020-04-28       Impact factor: 3.641

3.  Biological feasibility and importance of a gonorrhea vaccine for global public health.

Authors:  Leah R Vincent; Ann E Jerse
Journal:  Vaccine       Date:  2018-04-18       Impact factor: 3.641

4.  Clinical Performance of the BD CTGCTV2 Assay for the BD MAX System for Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis Infections.

Authors:  Barbara Van Der Pol; Edith Torres-Chavolla; Salma Kodsi; Charles K Cooper; Thomas E Davis; Kenneth H Fife; Stephanie N Taylor; Michael H Augenbraun; Charlotte A Gaydos
Journal:  Sex Transm Dis       Date:  2021-02-01       Impact factor: 3.868

Review 5.  A profile of the binx health io® molecular point-of-care test for chlamydia and gonorrhea in women and men.

Authors:  Barbara Van Der Pol; Charlotte A Gaydos
Journal:  Expert Rev Mol Diagn       Date:  2021-07-12       Impact factor: 5.670

6.  Surfactant-enhanced DNA accessibility to nuclease accelerates phenotypic β-lactam antibiotic susceptibility testing of Neisseria gonorrhoeae.

Authors:  Emily S Savela; Nathan G Schoepp; Matthew M Cooper; Justin C Rolando; Jeffrey D Klausner; Olusegun O Soge; Rustem F Ismagilov
Journal:  PLoS Biol       Date:  2020-03-19       Impact factor: 8.029

Review 7.  Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature.

Authors:  Tingting Jiang; Xiang-Sheng Chen
Journal:  Int J Environ Res Public Health       Date:  2020-02-21       Impact factor: 3.390

Review 8.  Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics.

Authors:  Bismillah Mubeen; Aunza Nayab Ansar; Rabia Rasool; Inam Ullah; Syed Sarim Imam; Sultan Alshehri; Mohammed M Ghoneim; Sami I Alzarea; Muhammad Shahid Nadeem; Imran Kazmi
Journal:  Antibiotics (Basel)       Date:  2021-11-30

Review 9.  Systematic Literature Review and Quantitative Analysis of Health Problems Associated with Sexually Transmitted Neisseria gonorrhoeae Infection.

Authors:  Jane Whelan; Jennifer Eeuwijk; Eveline Bunge; Ekkehard Beck
Journal:  Infect Dis Ther       Date:  2021-07-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.